Pharmaceutical Research & Drug Development – Page 2

Reproducibility gaps during sponsor oversight – regulatory deficiency risk analysis

Detecting reproducibility gaps typically manifests as discrepancies in experimental outcomes across different studies or laboratories. Common symptoms include:Click to read the full article.

Study design not regulator-aligned during study audit – CAPA for study design gaps

Identifying symptoms signaling a mismatch between study design and regulatory requirements is the first step in addressing potential failures proactively. Common indicators may include:Click to read the full article.

Dose justification weak during sponsor oversight – CAPA for study design gaps

Identifying symptoms or signals of weak dose justification is crucial for initiating an effective investigation. Common indicators may include:Click to read the full article.

GLP readiness concerns during regulatory submission prep – FDA/EMA non-clinical expectations

Addressing GLP Readiness Issues During Regulatory Submission Preparations Good Laboratory Practice (GLP) compliance is critical in preclinical studies, as it lays the foundation for regulatory submissions to agencies such as…

Non-clinical toxicity findings during study audit – regulatory deficiency risk analysis

Analyzing Non-clinical Toxicity Findings in Study Audits to Mitigate Regulatory Risks In the realm of pharmaceutical drug development, ensuring the integrity and reliability of preclinical studies is paramount for advancing…

Study design not regulator-aligned during regulatory submission prep – CAPA for study design gaps

Identifying symptoms indicative of study design misalignments is the first step towards resolution. These signals may manifest during various stages, including planning, execution, and documentation of preclinical studies. Common examples…

Species selection questioned during program hold risk review – regulatory deficiency risk analysis

During the preclinical phase, multiple signals can suggest that the species selection may not be appropriate or compliant. Common symptoms include:Click to read the full article.

GLP readiness concerns during regulatory submission prep – regulatory deficiency risk analysis

Identifying symptoms or signals that suggest GLP readiness concerns is the first step in mitigating the risk of regulatory deficiency:Click to read the full article.

Study design not regulator-aligned during study audit – preventing clinical hold

During an audit or routine investigation, several signals may indicate a disconnect between study design and regulatory alignment. Identifying these symptoms early can help prevent potential issues from escalating into…

Study design not regulator-aligned during regulatory submission prep – regulatory deficiency risk analysis

The first step in identifying misalignment in study design is recognizing the symptoms or signals that hint at potential deficiencies. Below are some common indicators in the laboratory or operational…

Study design not regulator-aligned during program hold risk review – FDA/EMA non-clinical expectations

Identifying the signals of study design misalignment is crucial for timely intervention. Symptoms often manifest as unexpected results, deviation reports, or reviewer feedback that highlights deficiencies in study protocols. Here…

Species selection questioned during program hold risk review – CAPA for study design gaps

Investigating Species Selection Questions During Program Hold Risk Reviews In the fast-evolving landscape of pharmaceutical research, one of the critical components of successful drug development is the selection of appropriate…